No abstract

No abstract

Patients with AIDS-associated refractory watery diarrhea, especially those without identifiable pathogens, may respond favorably to subcutaneously administered octreotide. This drug deserves further study in a randomized, placebo-controlled trial.

SUMMARY Enprostil is a synthetic dehydro‐prostaglandin E2 with gastroduodenal ulcer‐healing and mucosal‐protective properties. One hundred and three healthy volunteers were randomized to receive capsules of enprostil 35 μg b.d. (the clinically recommended dose), enprostil 70 μg b.d., or placebo b.d. All underwent endoscopic assessment of the gastroduodenal mucosa, scored using a 0–4 scale, at baseline and on Days 3, 7, 14, 21 and 28 of dosing. Mean and median maximum scores demonstrated a dose response, and the mean maximum scores were statistically significantly higher for both enprostil groups on each endoscopy day when compared with placebo. The majority of enprostil‐treated subjects had petechial haemorrhages. The proportion of volunteers with small white‐based mucosal breaks (erosions) was significantly higher for the fundus in the enprostil 70‐μg group on Days 21 and 28 when compared with placebo, but there were no significant differences between treatment groups for any area on the other study days. The 70‐μg dose was

No abstract